

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Claim 1 (original) A method for treating pain in an individual comprising administering to the individual an amount of an anti-nerve growth factor (NGF) antibody and an amount of an opioid analgesic, whereby the anti-NGF antibody and the opioid analgesic in conjunction provide effective pain relief.

Claim 2 (original) The method of claim 1, wherein the opioid analgesic is selected from the group consisting of morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine.

Claim 3 (original) The method of claim 2, wherein the opioid analgesic is morphine.

Claim 4 (original) The method of claim 1 or 3, wherein the anti-NGF antibody binds human NGF.

Claim 5 (original) The method of claim 4, wherein the anti-NGF antibody binds human NGF with a binding affinity of about 10 nM or less than about 10 nM.

Claim 6 (original) The method of claim 1, wherein the anti-NGF antibody is a human antibody.

Claim 7 (original) The method of claim 1, wherein the anti-NGF antibody is a humanized antibody.

Claim 8 (original) The method of claim 1, wherein the pain is post-surgical pain.

Claim 9 (original) The method of claim 4, wherein the pain is post-surgical pain.

Claim 10 (withdrawn) A pharmaceutical composition for treating pain comprising an effective amount of an anti-NGF antibody and an opioid analgesic, and a pharmaceutically acceptable carrier.

Claim 11 (withdrawn) A kit for treating pain comprising an anti-NGF antibody, an opioid analgesic, and instructions for administering the anti-NGF antibody in conjunction with the opioid analgesic to treat pain.

Claim 12 (new) The method of claim 1, wherein the individual is a mammal.

Claim 13 (new) The method of claim 1, wherein the individual is a human.